The company's unique approach preserves useful immune responses in inflammatory, autoimmune, and degenerative diseases, such as transplant rejection, graft-versus-host-disease, and auto-immune diseases. AbolerIS Pharma's team of experts uses anti-CD45RC monoclonal antibody to deplete effector T cells and preserve regulatory and memory T cells, as well as IL-34 cytokine to induce tolerogenic macrophages/DCs and regulatory T cells. The company's goal is to advance novel drugs in areas of unmet medical needs by focusing on the development of novel and unique therapeutic approaches to induce immune tolerance.